A new, highly sensitive cell therapy was able to wipe out three different kinds of solid tumors in mice, an important advance in an area where CAR-T cells have long struggled. But significant ...

In an interview on treatments following failure of chimeric antigen receptor (CAR) T-cell therapy in multiple myeloma, Rahul Banerjee, MD outlines the theory behind potential therapeutic strategies ...

Researchers hope to undertake clinical studies in multiple cancers, including ovarian cancer, glioblastoma, and others.

A proof-of-concept study opens up an avenue for treating solid tumours that express low levels of a target antigen.

Gilead is now waiting upon the FDA’s approval of anito-cel, Arcellx’s lead candidate, slated for December 2026.

A new editorial perspective was published in Volume 17 of Oncotarget on February 20, 2026, titled "CAR-T therapy: Trailblazing CAR(ing) in cancer treatment." ...

Though CAR T cells have been effective against certain blood cancers, they have not been for solid tumors. Now, a new form of ...

What major challenge of traditional CAR-T does the in vivo alleviate/address? In addi | Dr Adrian Bot, Capstan Therapeutics, ...

In 2024, Professor Sebastian Kobold's research group at LMU University Hospital had already shown that the metabolite ...

I f your doctor has recommended chimeric antigen receptor (CAR) T-cell immunotherapy for large B-cell lymphoma (LBCL), you’ve likely already tried several standard treatments, and the cancer did not ...

RNA CAR T therapy Descartes‑08 targets BCMA‑positive plasma cells and delivers year‑long symptom relief in myasthenia gravis after a brief course, signaling a new era of durable treatment.